A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death. Mannion et al.

Published: 24 May 2024| Version 1 | DOI: 10.17632/822syk52yw.1
Contributors:
,
,
,
, Laura Ramos Garcia,
,
,
,
,
,
,
,
,
,
,
,
,
, Alfie Brennan,
,
, John Alexander,
,
, Wenxin Lyu,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,

Description

Original data from the images and western blots from the paper: A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death.

Files

Institutions

Institute of Cancer Research

Categories

Molecular Biology, Radiation, Cancer, Innate Immunity, Immune Checkpoint Inhibitor, Immunogenic Cell Death

Funding

Breast Cancer Now

Cancer Research UK

Licence